Chromis Therapeutics Competitors and Similar CompaniesClear all
Chromis Therapeutics's competitors and similar companies include CSL Behring, UCB, Genentech and Biogen.
 Chromis Therapeutics Chromis Therapeutics is a biopharmaceutical company focused on the development of treatments for chronic HBV infection. |  UCB UCB is a company that provides biopharmaceutical research and development solutions for neurological and immunological conditions. |  Genentech Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines. |  Biogen Biogen (formerly known as Biogen Idec) is a biopharmaceutical company that develops and delivers therapies for neurological and neurodegenerative diseases. | ||
Founding Date | Founding Date 2015 | Founding Date 1904 | Founding Date 1928 | Founding Date 1976 | Founding Date 1978 |
Type | Type Private | Type Subsidiary | Type Public | Type Subsidiary | Type Public |
Tags | |||||
Locations | Locations San Diego, US HQ | Locations King of Prussia, US HQ Broadmeadows, AU Parkville, AU Parkville, AU Wien, AT Mechelen, BE see more | Locations Brussels, BE HQ Melbourne, AU Vienna, AT Braine L'alleud, BE Braine L'alleud, BE Leuven, BE São Paulo, BR see more | Locations South San Francisco, US HQ Hillsboro, US Oceanside, US Portland, US South San Francisco, US South San Francisco, US South San Francisco, US see more | Locations Cambridge, US HQ Vicente López, AR Macquarie Park, AU Wien, AT Machelen, BE São Paul, BR Toronto, CA see more |
Employees | Employees 2 | Employees 7,5692% decrease | Employees 9,052 | Employees 18,077 | Employees 7,605 |
Valuation ($) | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 34.3 b | Valuation ($) N/A | Valuation ($) 26.7 b |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $7.9b (FY, 2020) | Revenue (est.) €7.4b (FY, 2025) | Revenue (est.) N/A | Revenue (est.) $9.9b (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods €1.4b (FY, 2025) | Cost of goods N/A | Cost of goods $2.4b (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit $4.5b (FY, 2020) | Gross profit €7.2b (FY, 2025) | Gross profit N/A | Gross profit $7.5b (FY, 2025) |
Net income | Net income N/A | Net income N/A | Net income €1.6b (FY, 2025) | Net income N/A | Net income $1.3b (FY, 2025) |
Operating ⚠ | |||||
Countries | Countries N/A | Countries 100 (Dec, 2020) | Countries 35 (FY, 2019) | Countries N/A | Countries N/A |
Phase I Trials Products | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 28 (Jul, 2025) | Phase I Trials Products 4 (FY, 2024) |
Phase II Trials Products | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products 19 (Jul, 2025) | Phase II Trials Products 6 (FY, 2024) |
Phase III Trials Products | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 41 (Jul, 2025) | Phase III Trials Products 11 (FY, 2024) |
For sources of this data, please see the company profile
View Company Profiles
UCB
HQ
Brussels, BE
Employees
9,052
UCB is a company that provides biopharmaceutical research and development solutions for neurological and immunological conditions.
View companyGenentech
HQ
South San Francisco, US
Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines.
View companyBiogen
HQ
Cambridge, US
Employees
7,605
Biogen (formerly known as Biogen Idec) is a biopharmaceutical company that develops and delivers therapies for neurological and neurodegenerative diseases.
View company